Successful identification of complex rearrangements involving multiple chromosomes in burkitt-type/mature B-cell acte lymphoblastic leukemia: further emphasis on spectral karyotyping
A. Kakimoto, Kaori Otsubo, H. Saito, N. Komatsu, A. Ohsaka
{"title":"Successful identification of complex rearrangements involving multiple chromosomes in burkitt-type/mature B-cell acte lymphoblastic leukemia: further emphasis on spectral karyotyping","authors":"A. Kakimoto, Kaori Otsubo, H. Saito, N. Komatsu, A. Ohsaka","doi":"10.15406/MOJPB.2018.07.00216","DOIUrl":null,"url":null,"abstract":"Mature B-cell acute lymphoblastic leukemia (ALL) or Burkitt-type ALL is a rare entity and can be defined as the leukemic manifestation of Burkitt lymphoma (BL).1 BL is a highly aggressive B-cell malignancy and can be endemic, sporadic, or associated with immunodeficiency.2,3 Sporadic BL accounts for 1-2% of all adult lymphoma in Western Europe and the United States.2 Mature B-cell ALL is characterized by the expression of pan-/mature B-cell antigens (e.g., HLA-DR, CD19, cyCD22, and CD79α), together with surface immunoglobulin (sIg) accompanying light chain restriction, the association of an L3 morphology according to the FAB classification, and the presence of 8q24/MYC rearrangement.1-3 The MYC gene is most frequently found to be translocated into the Ig heavy chain locus (IGH), resulting in t(8;14)(q24;q32), whereas the less frequently observed variant translocations, t(2;8)(p12;q24) or t(8;22)(q24;q11), juxtapose MYC to the light chain kappa or lambda locus, respectively.1-3 However, there are often discrepancies between the morphology, immunophenotype, and genotype, leading to a heterogenous disease spectrum.","PeriodicalId":18585,"journal":{"name":"MOJ proteomics & bioinformatics","volume":"58 9","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2018-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"MOJ proteomics & bioinformatics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.15406/MOJPB.2018.07.00216","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Mature B-cell acute lymphoblastic leukemia (ALL) or Burkitt-type ALL is a rare entity and can be defined as the leukemic manifestation of Burkitt lymphoma (BL).1 BL is a highly aggressive B-cell malignancy and can be endemic, sporadic, or associated with immunodeficiency.2,3 Sporadic BL accounts for 1-2% of all adult lymphoma in Western Europe and the United States.2 Mature B-cell ALL is characterized by the expression of pan-/mature B-cell antigens (e.g., HLA-DR, CD19, cyCD22, and CD79α), together with surface immunoglobulin (sIg) accompanying light chain restriction, the association of an L3 morphology according to the FAB classification, and the presence of 8q24/MYC rearrangement.1-3 The MYC gene is most frequently found to be translocated into the Ig heavy chain locus (IGH), resulting in t(8;14)(q24;q32), whereas the less frequently observed variant translocations, t(2;8)(p12;q24) or t(8;22)(q24;q11), juxtapose MYC to the light chain kappa or lambda locus, respectively.1-3 However, there are often discrepancies between the morphology, immunophenotype, and genotype, leading to a heterogenous disease spectrum.